FDA Reassesses Ban on Compounding Pharmacies Supplying Cheaper Versions of Eli Lilly’s Weight Loss Drugs

The FDA is reconsidering its decision to ban compounding pharmacies from supplying cheaper versions of Eli Lilly’s blockbuster weight loss and diabetes drugs, Mounjaro and Zepbound. This comes after a lawsuit filed by compounding groups challenging the FDA’s restriction. Eli Lilly has also issued cease-and-desist letters to companies offering similar products, citing potential safety concerns.

Scroll to Top